Drugs / MURLENTAMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02978755 | Jun 2016 → Jun 2020 | female reproductive system neoplasm | GamaMabs Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03799731 | Jul 2018 → Jan 2021 | colorectal cancer | GamaMabs Pharma | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MURLENTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095339 ↗ |
| Known as | GM102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02978755 ↗ |
| Action | Deplete | “to trigger ADCC (antibody dependent cellular cytotoxicity) and phagocytosis of tumor cells.” NCT03799731 ↗ |
| Modality | Monoclonal antibody | “GM102 is a humanized low fucose monoclonal antibody” NCT02978755 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT03799731 ↗ |
| Target | AMHR2 | “GM102 is a humanized low fucose monoclonal antibody with a high affinity to AMHRII receptor.” NCT02978755 ↗ |